focus -WSS

focus

author：comprehensive 2025-08-11 09:46:09 - browse：8

Illustration of a bear on a red arrow with a bull underneath pushing the arrow upward. -- biotech coverage from STAT — Adobe

This was supposed to be the year of the biotech comeback, when promising new medicines and high-dollar buyouts would reverse a sector-wide slump that dates back to 2021. Instead, biotech stocks have dramatically underperformed the broader market, and the year’s few green shoots are yet to grow into a turnaround.

The closely watched XBI biotech index has fallen more than 10% in 2023, while the S&P 500 rose about 13% in the same period. Privately held companies have struggled to raise new capital without taking a hit to their valuations, and biotech IPOs have been rare in number and inconsistent in return.

The problem, analysts and investors said, is that the generalist investors who steer trillions of dollars of capital have simply soured on biotech. The furor over novel weight loss medicines like Wegovy has largely been a Big Pharma phenomenon, and rising interest rates have steered fund managers away from risky biotech stocks. The sector has gone through boom and bust cycles in the past, and it’s difficult, if not impossible, to predict when the macro winds might change and make biotech as popular as it was in the early days of Covid-19.

Get unlimited access to award-winning journalism and exclusive events.

Subscribe Log In

Previous article： What does generative AI mean for health care? We asked experts
Next article： How artificial intelligence is being used to detect, treat cancer

entertainment

focus

WSS

AI for drug discovery: Experts on separating hype from reality

Contact tracing may help avoid another lockdown. Can it work in the U.S.?

Caitlin Bernard's story shows physicians can't shy from advocacy

Death toll from an explosion and collapse of a Paris building in June climbs to 3

How a small hospital in rural Puerto Rico survived Hurricane Maria

What to know about Saharan dust affecting the US and how it can affect health

focus

focus

Wikipedia

Medicare details structure of new drug price negotiation program

AbbVie dramatically boosts its spending on lobbying

How to save PrEP access — and even expand it

Hyaluronic acid injections don’t help knee osteoarthritis, study finds

As demand for Covid shots wanes, Moderna seeks its next success

Most antidepressants don't work on kids, teens, study finds

Indiana Supreme Court upholds abortion ban, says state constitution gives only limited protections

AbbVie dramatically boosts its spending on lobbying

New air purifier tech could be key to improving indoor air quality

Brain MRIs reveal impact of 'toxic stress' on Black children

leisure time

Artificial intelligence advances fuel industry trying to preserve loved ones after death

Vatican is moving ahead with plan to reunite Ukrainian children taken to Russia with their families

Has Bernie Sanders reached the limit of his pharma bullying effort?

Warren pushes Witty on UnitedHealth's control over physicians

Marvel Studios reveals new trailer for 'The Marvels': Watch here

Class action alleges UnitedHealth concealed DOJ probe

hotspot

entertainment

focus

leisure time